Danilo Navarrete
Research Subjects
Danilo Navarrete has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Andres Orquera
Hematology Service, Carlos Andrade Marín Hospital, Quito, Ecuador
2 shared publications - Brenner Sabando
IRHED Medical Specialties Center Guayaquil Ecuador
2 shared publications - Jhoanna Ramirez
Hematology Service, Teodoro Maldonado Carbo Hospital, Guayaquil, Ecuador
2 shared publications - Maria Augusta Pacheco
Hemato-Oncology and Medicine Transfusion Department, Solca Cancer Institute, Cuenca, Ecuador
2 shared publications - Carlos Plaza
10 Hemato-Oncology and Medicine Transfusion Department, Solca Cancer Institute, Guayaquil, Ecuador
1 shared publication Jairo Quinonez
Department of Hematology, IRHED Medical Specialties Center, Guayaquil, Ecuador
1 shared publication
Latest Publications
- 13 November 2025
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 3 (4) , 82-89
Adults philadelphia-positive B–acute lymphoblastic leukemia in a moderate health access and quality index Country
Aims: to describe clinical and demographic characteristics, as well as to evaluate response and survival outcomes in Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) Ecuadorian adults. Methods: A retrospective, multicenter cohort study in patients aged >15 years diagnosed with Ph+ B-cell ALL was carried out. Diagnosis of B-ALL was established based on 2016 WHO classification and Ph+ mutation was confirmed in all cases. Results: 61 (12.4%) were identified with Ph+ chromosome. 56 were included in the analysis, 33 (58.9%) were male, and median age was 40.5 years [interquartile range (IQR): 25–51; range: 16–85]. 46 (82.1%) subjects were treated with Imatinib. CR was achieved in 30 (53.6%) patients. MRD was reported in 13/41 (31.7%). Only 5/29 eligible patients underwent HSCT. 9 (16.1) died in induction phase, all deaths were attributed to bacterial infections. Relapse was recorded in 7 (12.5%). Median OS for total cohort was 11 months (95% CI 8.1–13.9), with a 5-year OS of 26.8%. Imatinib therapy [HR 0.44 (95% CI 0.19 – 0.98); p=0.046]; Imatinib 800mg dose [HR 0.30 (95% CI 0.11 – 0.83); p=0.020]; Hyper-CVAD protocol [HR 0.44 (95% CI 0.21 – 0.93); p=0.031] were associated to better OS. Conclusion: Response and survival outcomes in Ecuadorian population are poorer compared to high income countries caused by high rate of induction death, low availability of MRD monitoring, lack of standardization of treatment protocols, restricted access to HSCT, and delayed initiation to TKIs therapy.
- 13 November 2025
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 3 (4) , 82-89
Adults philadelphia-positive B–acute lymphoblastic leukemia in a moderate health access and quality index Country
Aims: to describe clinical and demographic characteristics, as well as to evaluate response and survival outcomes in Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) Ecuadorian adults. Methods: A retrospective, multicenter cohort study in patients aged >15 years diagnosed with Ph+ B-cell ALL was carried out. Diagnosis of B-ALL was established based on 2016 WHO classification and Ph+ mutation was confirmed in all cases. Results: 61 (12.4%) were identified with Ph+ chromosome. 56 were included in the analysis, 33 (58.9%) were male, and median age was 40.5 years [interquartile range (IQR): 25–51; range: 16–85]. 46 (82.1%) subjects were treated with Imatinib. CR was achieved in 30 (53.6%) patients. MRD was reported in 13/41 (31.7%). Only 5/29 eligible patients underwent HSCT. 9 (16.1) died in induction phase, all deaths were attributed to bacterial infections. Relapse was recorded in 7 (12.5%). Median OS for total cohort was 11 months (95% CI 8.1–13.9), with a 5-year OS of 26.8%. Imatinib therapy [HR 0.44 (95% CI 0.19 – 0.98); p=0.046]; Imatinib 800mg dose [HR 0.30 (95% CI 0.11 – 0.83); p=0.020]; Hyper-CVAD protocol [HR 0.44 (95% CI 0.21 – 0.93); p=0.031] were associated to better OS. Conclusion: Response and survival outcomes in Ecuadorian population are poorer compared to high income countries caused by high rate of induction death, low availability of MRD monitoring, lack of standardization of treatment protocols, restricted access to HSCT, and delayed initiation to TKIs therapy.
- Open Access
- 1 January 2025
- Published by Wiley in Advances in Hematology
- Vol. 2025 (1)
Hyper‐CVAD in Adults With Acute Lymphoblastic Leukemia in Ecuador: A Multicenter Retrospective Study
Background: The Hyper‐CVAD protocol is a chemotherapy regimen widely used in hematological malignancies. It is considered one of most promising remission‐leading treatment option for adults with acute lymphoblastic leukemia (ALL). Objective: To determine the outcomes of adults with ALL treated with the Hyper‐CVAD protocol in Ecuador. Methods: This multicenter, retrospective, cross‐sectional study compared the outcomes of ALL patients aged 15 years and older treated with hyper‐CVAD protocol in 8 specialized centers. Results: 139 patients with ALL treated with the Hyper‐CVAD protocol were included. A total of 79 were female (56.8%) and the majority had a B‐type phenotype 130 (93.5%). A complete response (CR) was achieved in 64.3%. Relapse was confirmed in 52.7% of those who obtained CR. Negative minimal residual disease (MRD) was achieved in 20% of patients. The median overall survival (OS) was 11 months (95% CI: 7.49–14.50) with a 5‐year OS of 14.0%. A total of 12 (8.6%) deceased during induction phase. Conclusion: Adult patients treated with the Hyper‐CVAD protocol in Ecuador achieve rates of CR, MRD, and OS lower than those presented in international cohorts, as well as higher rates of treatment‐related toxicity.
- 1 January 2025
- Published by Wiley in Advances in Hematology
- Vol. 2025 (1)
Open AccessHyper‐CVAD in Adults With Acute Lymphoblastic Leukemia in Ecuador: A Multicenter Retrospective Study
Background: The Hyper‐CVAD protocol is a chemotherapy regimen widely used in hematological malignancies. It is considered one of most promising remission‐leading treatment option for adults with acute lymphoblastic leukemia (ALL). Objective: To determine the outcomes of adults with ALL treated with the Hyper‐CVAD protocol in Ecuador. Methods: This multicenter, retrospective, cross‐sectional study compared the outcomes of ALL patients aged 15 years and older treated with hyper‐CVAD protocol in 8 specialized centers. Results: 139 patients with ALL treated with the Hyper‐CVAD protocol were included. A total of 79 were female (56.8%) and the majority had a B‐type phenotype 130 (93.5%). A complete response (CR) was achieved in 64.3%. Relapse was confirmed in 52.7% of those who obtained CR. Negative minimal residual disease (MRD) was achieved in 20% of patients. The median overall survival (OS) was 11 months (95% CI: 7.49–14.50) with a 5‐year OS of 14.0%. A total of 12 (8.6%) deceased during induction phase. Conclusion: Adult patients treated with the Hyper‐CVAD protocol in Ecuador achieve rates of CR, MRD, and OS lower than those presented in international cohorts, as well as higher rates of treatment‐related toxicity.